Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2VIP
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
2VIP is a combination chemotherapy and targeted therapy regimen being evaluated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL). Developed by the Institute of Hematology & Blood Diseases Hospital in China, the regimen consists of inotuzumab ozogamicin (an anti-CD22 antibody-drug conjugate), venetoclax (a BCL-2 inhibitor), vincristine (a microtubule inhibitor), and prednisone (a corticosteroid). This regimen is typically used as part of a multi-phase treatment protocol that includes induction, consolidation, and maintenance, often integrated with other immunotherapies like blinatumomab or CAR-T cell therapy to improve event-free survival and minimal residual disease (MRD) negativity rates.
- Other names
- inotuzumab ozogamicin + venetoclax + vincristine + prednisone
02
Targets
CD22 (Cluster of Differentiation 22)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on 2VIP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2VIP.